drugset
drugset / Trial / NCT03058822

Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial

NCT03058822 ↗

Phase 1 Terminated 5 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelOther

Summary

A Phase 1, relative bioavailability study of BMS-931699 from prefilled syringe compared to drug in vial

Timeline

Start
2017-01-25
Primary completion
2017-03-30
Completion
2017-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject lulizumab pegol Monoclonal antibody — Subcutaneous

Indications

No indication recorded.